Recursion (@recursionpharma) 's Twitter Profile
Recursion

@recursionpharma

Decoding biology to radically improve lives. The industrial revolution of drug discovery is here.

ID: 2615770806

linkhttp://www.recursion.com calendar_today10-07-2014 16:41:56

3,3K Tweet

14,14K Followers

780 Following

Recursion (@recursionpharma) 's Twitter Profile Photo
Recursion
@recursionpharma

3 months ago

Today we announced that the first patient has been dosed in our Phase 1 trial of REC-3565 – a potential best-in-class MALT1 inhibitor for the treatment of relapsed or refractory B-cell lymphomas which impacts approximately 41,000 patients in the U.S. and EU5. 🔹 On REC-3565

Today we announced that the first patient has been dosed in our Phase 1 trial of REC-3565 – a potential best-in-class MALT1 inhibitor for the treatment of relapsed or refractory B-cell lymphomas which impacts approximately 41,000 patients in the U.S. and EU5. 🔹 On REC-3565